| | | | | | | | | | |
|
| |
|
| Dockets Entered
On November 4, 2005
Table of Contents
|
|
|
|
|
|
|
|
|
|
|
| Docket #
|
| Title
|
|
|
|
|
|
|
| 1976N-0052G
|
| OTC general comments & combinations
|
|
|
|
|
| 1997S-0162
|
| 30-Day Structure Function Claim Notification Letters Dietary
|
|
|
|
|
| 1999P-0796
|
| Stay the effective date of approval of ANDAs for Diprivan
|
|
|
|
|
| 2005N-0279
|
| Food Labeling; Gluten-Free Labeling of Foods; Public Meeting
|
|
|
|
|
| 2005N-0345
|
| Drug Approvals: Circumstances under which an active ingredient may be simultaneously marketed in both a prescription drug product and an over-the-counter drug product
|
|
|
|
|
| 2005P-0076
|
| OxyContin and Paladone removal from market and label changes limiting indications to severe chronic pain
|
|
|
|
|
| 2005P-0116
|
| To take the following actions with regard to aqueous-based drugs for inhalation that has been compounded by pharmacy operations
|
|
|
|
|
| 2005P-0397
|
| Classification of Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene Mutation Detection System
|
|
|
|
|
| 2005P-0430
|
| Requests that the Commissioner of Food and Drugs recommend scheduling of tramadol under the Controlled Substances Act.
|
|
|
|
|
| 1976N-0052G
|
| OTC general comments & combinations
|
|
|
|
|
| C
231
|
| Bayer Healthcare, LLC
|
| Vol #:
|
| 38
|
|
|
|
|
| 1997S-0162
|
| 30-Day Structure Function Claim Notification Letters Dietary
|
|
|
|
|
| LET
16783
|
| Ajinomoto USA, Inc.
|
| Vol #:
|
| 151
|
|
|
|
|
| LET
16784
|
| Ajinomoto USA Inc.
|
| Vol #:
|
| 151
|
|
|
|
|
| LET
16785
|
| Ajinomoto USA Inc.
|
| Vol #:
|
| 151
|
|
|
|
|
| LET
16786
|
| Ajinomoto USA Inc.
|
| Vol #:
|
| 151
|
|
|
|
|
| LET
16787
|
| Boots Retail USA Inc.
|
| Vol #:
|
| 151
|
|
|
|
|
| LET
16788
|
| Boots Retail USA Inc.
|
| Vol #:
|
| 151
|
|
|
|
|
| LET
16789
|
| Boots Retail USA Inc.
|
| Vol #:
|
| 151
|
|
|
|
|
| LET
16790
|
| Ajinomoto USA Inc.
|
| Vol #:
|
| 151
|
|
|
|
|
| LET
16791
|
| Univera, Inc., d.b.a. Oasis LifeSciences
|
| Vol #:
|
| 151
|
|
|
|
|
| LET
16792
|
| Enzymatic Therapy
|
| Vol #:
|
| 151
|
|
|
|
|
| LET
16793
|
| Enzymatic Therapy
|
| Vol #:
|
| 151
|
|
|
|
|
| LET
16794
|
| Enzymatic Therapy
|
| Vol #:
|
| 151
|
|
|
|
|
| LET
16795
|
| Enzyamtic Therapy
|
| Vol #:
|
| 151
|
|
|
|
|
| LET
16796
|
| Enzymatic Therapy
|
| Vol #:
|
| 151
|
|
|
|
|
| LET
16797
|
| Herbalife International of America, Inc.
|
| Vol #:
|
| 151
|
|
|
|
|
| 1999P-0796
|
| Stay the effective date of approval of ANDAs for Diprivan
|
|
|
|
|
| WDL
1
|
| AstraZeneca Pharmaceuticals, LP
|
| Vol #:
|
| 1
|
|
|
|
|
| 2005N-0279
|
| Food Labeling; Gluten-Free Labeling of Foods; Public Meeting
|
|
|
|
|
| C 664
|
| A. Hamburk
|
| Vol #:
|
| 23
|
|
|
|
|
| C
665
|
| Center for Science in the Public Interest (CSPI)
|
| Vol #:
|
| 23
|
|
|
|
|
| 2005N-0345
|
| Drug Approvals: Circumstances under which an active ingredient may be simultaneously marketed in both a prescription drug product and an over-the-counter drug product
|
|
| | | | | | | |
|
| |
|
| ANS
45
|
| HFW-1 to Honorable Maurice D. Hinchey
|
| Vol #:
|
| 99
|
|
|
|
|
| ANS
46
|
| HFW-1 to Honorable Jane Harman
|
| Vol #:
|
| 99
|
|
|
|
|
| ANS
47
|
| HFW-1 to Honorable Luis V. Gutierrez
|
| Vol #:
|
| 99
|
|
|
|
|
| ANS
48
|
| HFW-1 to Honorable Raul M. Grijalva
|
| Vol #:
|
| 99
|
|
|
|
|
| ANS
49
|
| HFW-1 to Honorable Sam Farr
|
| Vol #:
|
| 99
|
|
|
|
|
| ANS
50
|
| HFW-1 to Honorable Anne G. Eshoo
|
| Vol #:
|
| 99
|
|
|
|
|
| ANS
51
|
| HFW-1 to Honorable William D. Delahunt
|
| Vol #:
|
| 99
|
|
|
|
|
| ANS
52
|
| HFW-1 to Honorable Peter A. DeFazio
|
| Vol #:
|
| 99
|
|
|
|
|
| ANS
53
|
| HFW-1 to Honorable Susan A. Davis
|
| Vol #:
|
| 99
|
|
|
|
|
| ANS
54
|
| HFW-1 to Honorable Elijah E. Cummings
|
| Vol #:
|
| 99
|
|
|
|
|
| ANS
55
|
| HFW-1 to Honorable Julia M. Carson
|
| Vol #:
|
| 99
|
|
|
|
|
| ANS
56
|
| HFW-1 to Honorable Russ Carnahan
|
| Vol #:
|
| 99
|
|
|
|
|
| ANS
57
|
| HFW-1 to Honorable Michael E. Capuano
|
| Vol #:
|
| 99
|
|
|
|
|
| ANS
58
|
| HFW-1 to Honorable Lois Capps
|
| Vol #:
|
| 99
|
|
|
|
|
| ANS
59
|
| HFW-1 to Honorable Sherrod Brown
|
| Vol #:
|
| 99
|
|
|
|
|
| ANS
60
|
| HFW-1 to Honorable Earl Blumenauer
|
| Vol #:
|
| 99
|
|
|
|
|
| ANS
61
|
| HFW-1 to Honorable Tammy Baldwin
|
| Vol #:
|
| 99
|
|
|
|
|
| ANS 62
|
| HFW-1 to Honorable Louise M. Slaughter
|
| Vol #:
|
| 99
|
|
|
|
|
| ANS 63
|
| HFW-1 to Honorable Tom Lantos
|
| Vol #:
|
| 99
|
|
|
|
|
| ANS 64
|
| HFW-1 to Honorable Diana DeGette
|
| Vol #:
|
| 99
|
|
|
|
|
| ANS 65
|
| HFW-1 to Honorable Rosa L. DeLauro
|
| Vol #:
|
| 99
|
|
|
|
|
| ANS 66
|
| HFW-1 to Honorable Judy Biggert
|
| Vol #:
|
| 99
|
|
|
|
|
| ANS 67
|
| HFW-1 to Honorable Sherwood L. Boehlert
|
| Vol #:
|
| 99
|
|
|
|
|
| ANS 68
|
| HFW-1 to Honorable Nancy L. Johnson
|
| Vol #:
|
| 99
|
|
|
|
|
| ANS 69
|
| HFW-1 to Honorable Joe Baca
|
| Vol #:
|
| 99
|
|
|
|
|
| ANS 70
|
| HFW-1 to Honorable Thomas H. Allen
|
| Vol #:
|
| 99
|
|
|
|
|
| ANS 71
|
| HFW-1 to Honorable Neil Abercrombie
|
| Vol #:
|
| 99
|
|
|
|
|
| ANS 72
|
| HFW-1 to Honorable Christopher Shays
|
| Vol #:
|
| 99
|
|
|
|
|
| ANS 73
|
| HFW-1 to Honorable Henry A. Waxman
|
| Vol #:
|
| 99
|
|
|
|
|
| ANS 74
|
| HFW-1 to Honorable Mark Steven Kirk
|
| Vol #:
|
| 99
|
|
|
|
|
| ANS 75
|
| HFW-1 to Honorable Nita M. Lowey
|
| Vol #:
|
| 99
|
|
|
|
|
| C
448
|
| Ibis Reproductive Health
|
| Vol #:
|
| 99
|
|
|
|
|
| C
449
|
| National Asian Pacific American Women's Forum (NAPAWF)
|
| Vol #:
|
| 99
|
|
|
|
|
| C
450
|
| American Civil Liberties Union (ACLU)
|
| Vol #:
|
| 99
|
|
|
|
|
| C 451
|
| C. Dixon
|
| Vol #:
|
| 99
|
|
|
|
|
| C 452
|
| Mr and Mrs A. Durkin
|
| Vol #:
|
| 99
|
|
|
|
|
| C
453
|
| Aventis Pharmaceuticals, Inc and Sanofi-Synthelabo, Inc.
|
| Vol #:
|
| 99
|
|
